Skip to content

The efficacy and safety of Ganduqing granule for treating common cold with qi deficiency leading to lingering of evil syndrome: a randomized, double-blind, placebo, parallel-group, multicenter- controlled trial

The efficacy and safety of Ganduqing granule for treating common cold with qi deficiency leading to lingering of evil syndrome: a randomized, double-blind, placebo, parallel-group, multicenter- controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026714
Enrollment
Unknown
Registered
2019-10-19
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common Cold

Interventions

Sponsors

Hospital of of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnosis of common cold according to Western medicine; (2) Meet the diagnosis of common cold with qi deficiency syndrome according to Traditional Chinese Medicine; (3) Repeated colds every year, more than 4 times; (4) Symptom presenting within 48 hours; (5) Aged between 18 and 70 years; (6) Voluntarily participate and provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Influenza; (2) Patient's body temperature over 39 degree C; (3) White blood cell count > 12.0 x 10^9/L and/or neutrophil percentage > 80%; (4) Patients with other infectious diseases of the respiratory tract, such as acute herpetic pharyngitis, acute viral pharyngitis, acute herpetic laryngitis, acute viral laryngitis, acute tonsillitis, and pneumonia; (5) Liver function levels (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) 1.5 times higher than the upper limit of normal or abnormal serum creatinine; (6) Allergic or possibility of being allergic to the ingredients in the study drug; (7) Patients with severe cardio-cerebrovascular, lung, kidney or hematopoietic system diseases; (8) Patients who have participated in other drug clinical trials within one month or are participating in other drug clinical trials; (9) Other medicines (including cold, antibiotics, antivirals and similar traditional Chinese medicines) that have been used to treat the disease since symptom presenting within 48 hours; (10) Pregnant and lactating women; (11) Psychiatric patients; (12) Identified by the investigator as inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Duration of all symptoms to resolve or heal from treatment.;Single symptom duration;Improvement in primary symptoms;

Secondary

MeasureTime frame
Improvement in secondary symptoms;Changes of TCM symptom score;

Countries

China

Contacts

Public ContactFei Wang

Chengdu University of Traditional Chinese Medicine

wangfei896@163.com+86 1880880213

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026